FDA warning to Dr Reddy's Mexican unit will have limited business impact
This article was originally published in Scrip
The US FDA's warning letter to Dr Reddy's Laboratories' Mexican intermediates and active pharmaceutical ingredients facility over good manufacturing practice (GMP) deviations is expected to have a limited impact on the firm's earnings at least for now, in view of the unit's low contribution to Dr Reddy's bottom line.
You may also be interested in...
Aurobindo and Sandoz mutually terminate their planned $1bn deal, leaving many questions on how both sides will re-orient strategies going forward.
Takeda appoints new country head for India and aims to improve patient access to innovative medicines in the largely out-of-pocket market.
The coronavirus pandemic has thrown up unprecedented challenges for the Indian clinical trials segment, as in other parts of the world. Experts tell Scrip how things are poised in the country including potential impact on some critical milestones, but efforts are underway to tackle the crisis.